Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2025
Reporting Period: Quarter and full year ended December 31, 2024.
This filing announces the release of financial results for the specified period. The detailed financial data is contained in the press release filed as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover report and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1).
Accounting Basis: Results are presented on both GAAP and non-GAAP bases. Management utilizes non-GAAP measures for internal operating, budgeting, and financial planning. Reconciliations between GAAP and non-GAAP figures are located on pages 11, 12, and 13 of the press release.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. Investors must refer to Exhibit 99.1 for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: Management asserts that non-GAAP information is useful for investors when considered alongside GAAP statements but notes that non-GAAP measures may be defined differently by other companies in the industry.
Legal Disclaimer: Information in Item 2.02 and Item 9.01, including the press release, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to liabilities under that section. It shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2024.
- Examine pages 11-13 of the press release for the reconciliation between GAAP and non-GAAP financial measures.
- Verify the specific definitions of non-GAAP metrics used by Gilead to ensure comparability with industry peers.
- Confirm the full text of the press release for any forward-looking guidance or risk factors not summarized in this 8-K.